| 2.57 0.2 (8.44%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.54 | 1-year : | 4.28 |
| Resists | First : | 3.03 | Second : | 3.67 |
| Pivot price | 2.34 |
|||
| Supports | First : | 2 | Second : | 1.67 |
| MAs | MA(5) : | 2.3 |
MA(20) : | 2.48 |
| MA(100) : | 2.06 |
MA(250) : | 2.01 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 54.4 |
D(3) : | 37.2 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 5.46 | Low : | 0.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CABA ] has closed below upper band by 8.5%. Bollinger Bands are 20.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.47 | 2.47 - 2.48 |
| Low: | 2.17 - 2.18 | 2.18 - 2.2 |
| Close: | 2.35 - 2.37 | 2.37 - 2.4 |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Tue, 11 Nov 2025
Cabaletta Bio Draws Analyst Praise Despite Growing Losses - Finimize
Mon, 10 Nov 2025
Cabaletta Bio Advances in Autoimmune Therapy Development - TipRanks
Mon, 10 Nov 2025
Cabaletta Bio (CABA) Q3 Earnings Beat Expectations - GuruFocus
Tue, 04 Nov 2025
Cabaletta Bio (Nasdaq: CABA) offers webcasts across Nov–Dec conferences; 30-day replays - Stock Titan
Tue, 04 Nov 2025
Cabaletta Bio (CABA): Assessing Valuation After Promising Clinical Trial Results and Growing Investor Interest - Yahoo Finance
Sun, 02 Nov 2025
Cabaletta Bio Stock Price Rises After Positive Clinical Data Announcement - timothysykes.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 96 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 78 (%) |
| Shares Short | 12,950 (K) |
| Shares Short P.Month | 6,040 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.9 % |
| Return on Equity (ttm) | -101.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -119 (M) |
| Levered Free Cash Flow | -76 (M) |
| PE Ratio | -1.08 |
| PEG Ratio | 0 |
| Price to Book value | 1.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|